InvVax was incorporated in January 2013. Located in sunny Southern California, it maintains a strong affiliation with the UCLA, where its technology was originally developed. InvVax has access to a wide network of leading investigators in diverse disciplines, including molecular virology, immunology, pharmacology, and clinical infectious diseases. SNNLive spoke with Matt Sand, CEO of InvVax at First Look LA 2014 presented by LAVA in Los Angeles, CA.
“Arthur Young, the founder and president, spent three years of his life going through 13,000 nucleotide positions on the flu genome to identify the 28 truly invariant regions of the virus and those are the targets for our vaccine – we’re creating the first universal flu vaccine,” begins Mr. Sand. He continues, “The virus basically has two options, one it can mutate and die – if it mutates, if it doesn’t mutate it will be targeted by our vaccine.”
Mr. Sand explains, “We’ve accomplished the first of two major milestones in our preclinical work, the second milestone we hope to achieve in the next six months and we need to conduct some toxicology studies after that which is fairly straightforward but it’ll take about 12 months, so we’re looking at about 18 months to begin human trials.” SNNLive welcomes Matt Sand, CEO of InvVax. For more information, check out their website at www.inv-vax.com
© 2017 Stock News Now
Supported by Superior Web Solutions